Literature DB >> 3405

Adriamycin metabolism in man. Evidence from urinary metabolites.

S Takanashi, N R Bachur.   

Abstract

We studied the human metabolism of adriamycin by isolating and identifying urinary metabolites which retain adriamycin's specific fluorescence properties. Metabolites were extracted by adsorption to polystyrene polymeric sorbants, separated on silicic acid columns and purified by thin-layer chromatography. Structures were determined by comparative chromatography; infrared, fluorescence, and mass spectroscopy; and enzymatic and chemical degradation. Substances identified were adriamycinol, adriamycinol aglycone, adriamycin aglycone, deoxyadriamycin aglycone, deoxyadriamycinol aglycone, demethyldeoxyadriamycinol aglycone, demethyldeoxyadriamycinol aglycone 4-O-sulfate, and demethyldeoxyadriamycinol aglycone 4-O-beta-glucuronide. Other metabolites have been purified but not identified. Human metabolism of adriamycin involved carbonyl reduction, reductive glycosidic cleavage, hydrolytic glycosidic cleavage, O-demethylation, O-sulfation, and O-beta-glucuronidation. Carbonyl reduction was the major enzymatic conversion occurring in the human.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 3405

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  52 in total

1.  Quantification of Doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandem mass spectroscopy.

Authors:  Robert D Arnold; Jeanine E Slack; Robert M Straubinger
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2004-09-05       Impact factor: 3.205

Review 2.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

3.  Capillary electrophoresis monitors enhancement in subcellular reactive oxygen species production upon treatment with doxorubicin.

Authors:  Angela R Eder; Edgar A Arriaga
Journal:  Chem Res Toxicol       Date:  2006-09       Impact factor: 3.739

4.  Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans.

Authors:  K Mross; U Mayer; K Hamm; K Burk; D K Hossfeld
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function.

Authors:  P S Mushlin; B J Cusack; R J Boucek; T Andrejuk; X Li; R D Olson
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

6.  Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.

Authors:  G Minotti; A F Cavaliere; A Mordente; M Rossi; R Schiavello; R Zamparelli; G Possati
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography.

Authors:  D E Brenner; S Galloway; J Cooper; R Noone; K R Hande
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits.

Authors:  N L Harris; D E Brenner; L B Anthony; J C Collins; S Halter; K R Hande
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs.

Authors:  A A Gabizon; Y Barenholz; M Bialer
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

Review 10.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.